Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca/Actavis Antibiotic Faces Limited Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA allowed flexibility in AstraZeneca/Actavis’ gram-negative antibiotic development program, but agency’s advisory committee briefing documents propose more restrictive label than companies are seeking.

You may also be interested in...



FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway

FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.

Lilly CEO: Realistic Expectations Needed For Current Wave of Alzheimer’s Treatments

Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.

New FDA Fecal Transplant Guidance Should Ease Ferring’s Path To Commercialization

Final guidance excludes stool banks, putting in place more limited enforcement discretion regarding the requirement of an investigational new drug application for use of fecal transplants to treat C. diff infections, likely paving way for shift to any FDA-approved product.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel